Efficient gene delivery is a critical obstacle for gene therapy that must be overcome. Until current limits of gene delivery technology are solved, identification of systems with bystander effects is highly desirable. As an anticancer agent, radioactive iodine 131 I has minimal toxicity. The physical characteristics of 131 I decay allow radiation penetration within a local area causing bystander killing of adjacent cells. Accumulation of 131 I mediated by the sodium iodide symporter (NIS) provides a highly effective treatment for well-differentiated thyroid carcinoma. Other types of cancer could also be treated by NIS-mediated concentration of lethal 131 I radiation in tumor cells. Our group and others previously reported that a significant antitumor effect in mice was achieved after adenoviral delivery of rat or human NIS gene following administration of 3 mCi of 131 I. We have also demonstrated 5-6-fold greater uptake of 125 I by rat NIS over human NIS in human cancer cells. Recently, we reported the capability of the rat NIS and 131 I to effectively induce growth arrest of relatively large tumors (approximately 800 mm 3 ) in an animal model. In the present work tumor growth inhibition was achieved using adenoviral delivery of the rat NIS gene and 1 mCi of 131 I (one-third of the dose used in earlier reports). We also demonstrated that a higher concentration of 123 I was accumulated in the NIS-expressing tumors than in the thyroid 20 min after radioiodine administration. The highest intratumoral radioiodine concentration was observed along the needle track; however, the rat NIS-131 I effectively induced growth arrest of tumor xenografts in mice through its radiological bystander effect. Importantly, the rat NIS allowed reducing the injected radioiodine dose by 70% with the same antitumor efficacy in pre-established tumors. These results suggest that the rat NIS gene may be advantageous compared to the human gene in its ability to enhance intratumoral 131 I uptake.
I mediated by the sodium iodide symporter (NIS) provides a highly effective treatment for well-differentiated thyroid carcinoma. Other types of cancer could also be treated by NIS-mediated concentration of lethal 131 I radiation in tumor cells. Our group and others previously reported that a significant antitumor effect in mice was achieved after adenoviral delivery of rat or human NIS gene following administration of 3 mCi of 131 I. We have also demonstrated 5-6-fold greater uptake of 125 I by rat NIS over human NIS in human cancer cells. Recently, we reported the capability of the rat NIS and 131 I to effectively induce growth arrest of relatively large tumors (approximately 800 mm 3 ) in an animal model. In the present work tumor growth inhibition was achieved using adenoviral delivery of the rat NIS gene and 1 mCi of 131 I (one-third of the dose used in earlier reports). We also demonstrated that a higher concentration of 123 I was accumulated in the NIS-expressing tumors than in the thyroid 20 min after radioiodine administration. The highest intratumoral radioiodine concentration was observed along the needle track; however, the rat NIS- 131 I effectively induced growth arrest of tumor xenografts in mice through its radiological bystander effect. Importantly, the rat NIS allowed reducing the injected radioiodine dose by 70% with the same antitumor efficacy in pre-established tumors. These results suggest that the rat NIS gene may be advantageous compared to the human gene in its ability to enhance intratumoral 131 I uptake. I has minimal toxicity and is highly effective for treatment of well-differentiated thyroid carcinoma (WDTC). [3] [4] [5] The 10-year survival rate for middle-aged adults with WDTC is 80-90%. 6 Successful treatment of thyroid carcinoma is possible due to 131 I accumulation mediated by the sodium iodide symporter (NIS). [7] [8] [9] The NIS is a transmembrane glycoprotein found on the surface of thyroid cells and increases intracellular iodine concentration in thyroid gland cells 20-40-fold higher than plasma levels. 10,11 131 I therapy mediated by NIS concentration of lethal radiation could potentially be used to eradicate other tumor types with increased therapeutic indices. 12, 13 Our group and others previously reported very high levels of radioiodine uptake can be reached in vitro and in vivo after adenoviral delivery of NIS gene to nonthyroid tumor cells. 1, 12, [14] [15] [16] [17] [18] Using in vitro clonogenic assays we demonstrated that 50% of non-thyroid cancer cells transduced with rat NIS gene were killed after incubation with 131 I compared with nontransduced cells. 12 To evaluate the therapeutic efficacy of rat NIS and 131 I, Boland and colleagues 1 administered 30-90 mCi of 131 I to mice bearing Ad-NIS-injected tumors. In their study no difference in tumor size was observed between groups of animals treated with Ad-NIS-131 I and control groups, and one of the conclusions made was that the tumors did not retain iodide for a time period long enough to allow delivery of a lethal radiation. Spitzweg and colleagues 15 used human prostate cancer xenografts in athymic nude mice to explore the efficacy of NIS gene therapy, using recombinant adenovirus containing the human NIS gene. Importantly, a significant antitumor effect was demonstrated following administration of 3 mCi of 131 I. This study provided clear evidence that a therapeutic radioiodine dose could be achieved within the tumors using the human NIS.
Previously, we directly compared the human and rat NIS genes for their iodine-concentrating ability. Interestingly, within a variety of human tumor cell lines, perchlorate-sensitive 125 I uptake was consistently higher with the rat NIS gene (up to 5-fold greater) when compared to the human NIS gene. 19 We further demonstrated that the rat NIS gene can effectively induce growth arrest of human prostate tumor xenografts in mice after in vivo adenoviral gene delivery and administration of 3 mCi of 131 I. 16 Recently, we reported the capability of the rat NIS to effectively induce growth arrest of relatively large tumors (about 800 mm 3 ) in mice when treated with 3 mCi of 131 I. 20 The central limitation when translating NIS-131 I therapy from mouse models to humans is the inability to achieve an effective lethal dose per body weight equivalent to that observed in mice with 3 mCi of 131 I. It was important to test the antitumor effect of the NIS approach with a lower dose of 131 I. In this work, a high level of NIS expression in vitro was demonstrated when DU145 human prostate cancer cell monolayers were transduced with an adenoviral vector containing the rat NIS gene (Figure 1) . 125 I assays, performed in DU145 cells transduced with Ad-NIS ranging from 10 to 100 MOI, revealed that maximal expression of NIS was achieved with 50 MOI. Further increases in the viral infectious dose resulted in the same level of NIS expression shown by 125 I uptake assay and increased cytotoxicity (data not shown). In cellular monolayers, further elevation of NIS expression and, thus, radioiodine uptake could not be achieved by a concurrent increase in viral dose. While a viral dose 50 MOI results in a maximal level of NIS expression in two-dimensional tissue culture, this dose could not be adequately transferred to three-dimensional biological tissue (like tumors or spheroids) to achieve similar levels of NIS expression and transduction efficiency. Intratumoral injection of a replication-defective viral vector by syringe results in transgene expression mainly along the needle track and 5-10% tumor transduction efficiency. An imaging experiment using 123 I was performed to evaluate NIS expression in vivo. DU145 human prostate cancer xenografts were established in athymic nude mice, and Ad-NIS (10 8 PFU/mouse) was injected intratumorally. Imaging data demonstrated that the highest radioiodine concentration in the tumor was observed along the needle track (Figure 2a) . Interestingly, 123 I Figure 1 Rat sodium iodide symporter (NIS) expression in DU145 human prostate cancer cells transduced with adenoviral vector containing rat NIS gene.
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I uptake was measured in nontransduced cells and cells transduced with 10-100 MOI of Ad-NIS. DU145 cells were seeded into 24-well tissue culture plates and transduced with Ad-NIS. Forty-eight hours post-transduction, cells were analyzed for functional NIS activity using an 125 I uptake assay. Iodide uptake was initiated by adding HBSS containing 0.057-0.345 nM carrier-free Na 125 I and 5-300 mM NaI. 16 Cells were incubated (371C, 5% CO 2 ) for 30 min. Reactions were rapidly terminated by washing the cells with ice-cold HBSS, and cells were solubilized in 1% Triton X-100. The total radioactivity of accumulated iodide was measured using a gamma counter (Wallac, Turku, Finland). 21 DU145 cells were grown in a tissue culture flask to approximately 80% confluency, then transferred to a flask containing 1% Noble agar, and incubated 5-7 days (371C, 5% CO 2 ). Small tumor-like cell aggregates were transferred to a fresh flask with agar and incubated for an additional 7 days. Spheroids 50-100 mm in size were isolated by size exclusion using 50-mm and 100-mm sterile nylon mesh. The spheroids were transduced with 10 MOI of Ad-GFP. Forty-eight hours post-transduction, pictures of spheroids were taken using a Nicon Diaphot 300 fluorescent microscope. This figure represents a small spheroid (approximately 50 mm in diameter) photographed under normal visible (left) and fluorescent light (right).
Rat NIS for cancer gene therapy E Mitrofanova et al concentration in the tumor was greater than in the thyroid 20 min after radioiodine administration (prior to intrathyroidal organification of administered radioiodine), establishing that adenoviral delivery of the NIS gene resulted in very high level of NIS expression in the tumor.
The advantage of the NIS-131 I approach is the radiological bystander effect resulting from three-dimensional b-emission and cross-fire irradiation to neighboring nontransduced tumor cells making gene delivery to every cell unnecessary. Previously, using a retroviral vector for NIS gene delivery, we demonstrated that DU145 spheroids composed of 60-70% NIS-expressing cells were completely destroyed after exposure to 20 mCi of 131 I. 21 When DU145 spheroids formed from cells not expressing NIS were exposed to 20 mCi of 131 I, no toxicity was observed, and 100% of these spheroids survived. In a separate experiment, spheroids transduced with 10 MOI (a dose was estimated per total number of cells in an average spheroid) of Ad-NIS were killed by incubation with 20 mCi of 131 I. 16 Noticeably, spheroids transduced with 10 MOI of adenoviral vector encoding enhanced green fluorescent protein (GFP) revealed GFP expression exclusively in cells localized on the surface of the spheroids (Figure 2b) . Thus, concentration of 131 I radiation in NIS-positive cells was lethal to adjacent cells inside tumor spheroids, establishing an effective radiological bystander effect. This radiological bystander effect was also reported by Dingli and colleagues, 22 who used a lentiviral vector to stably transduce myeloma cells with the human NIS gene. They demonstrated no difference between growth inhibitions of myeloma I administration. When considering the dose of radioiodine to be used to achieve a therapeutic effect, one should remember that there is a tremendous difference between humans and mice. In humans, most administered radioiodine locates in the thyroid gland (with less in lactating mammary gland tissue). 23 In mice, there is a high level of radioiodine exposure to gastrointestinal tissue (Figure 2a) , partly as a result of a high level of expression of gastric NIS in rodents. 24 Therefore, the actual radioiodine dose accumulated in a mouse thyroid gland (or tumor) is lower than the administered dose. This fact may explain why Boland and colleagues 1 did not observe any therapeutic effect by administering 30-90 mCi of 131 I to mice bearing NIS-expressing tumors.
Since radioiodine in mice is accumulated in the thyroid gland, stomach, and NIS-expressing tumor cells, we used three-dimensional cancer spheroids to reveal differences between the effects of low dose (20 mCi) and high dose (1 mCi) radioiodine on the growth of spheroids (Figure 3) . In this experiment, we used an adenoviral vector for NIS gene delivery. All the spheroids, regardless of NIS expression, were killed by 1 mCi of 131 I (Figure 3c and d) . However, when the radioiodine dose was decreased to 20 mCi, the NISnegative spheroids continued to grow, while the NIS-expressing spheroids were killed, most likely by NIS-mediated concentration and translocation of radioiodine from the media to the spheroidal mass (Figure 3e and f). This experiment demonstrates a difference between intracellular (NIS-mediated) and extracellular 131 I irradiation of cancer cells, using a three-dimensional spheroid model.
In an animal model, Spitzweg and colleagues 15 employed 3 mCi to evaluate the therapeutic efficacy of human NIS-131 I and demonstrated strong tumor growth inhibition. Using the rat NIS and 3 mCi of 131 I, our group also demonstrated a strong antitumor effect against DU145 human prostate tumor xenografts. 16 Both these studies utilized adenoviral delivery of human or rat NIS gene to already established tumors in mice. Using tumor cells that were stably transduced or transfected with the human NIS gene, two other groups demonstrated the therapeutic effectiveness of the human NIS gene followed by 1 mCi of 131 I administration. 22, 25 No prior reports have shown effective treatment with 1 mCi of 131 I after in vivo gene delivery of the rat (or human) NIS gene into pre-established tumors in mice.
According to our previous data, the rat NIS provided 5-6-fold greater uptake of 125 I by human cancer cells than the human NIS and could theoretically allow utilizing a lower dose of radioiodine for therapy. In our present in vivo experiments, adenoviral delivery of the rat NIS gene and 1 mCi of radioiodine 131 I were employed to determine if tumor growth inhibition could be achieved. The experiment was performed using the DU145 human prostate tumor model. No statistical difference was observed between tumor growth inhibition with 1 mCi 131 I when compared with 3 mCi (Figure 4 ), while tumors in control groups of mice continued to grow. Thus, the rat NIS allowed reducing the injected radioiodine dose by 70% with the same antitumor efficacy in preestablished tumors. Since mouse gastric NIS concentrates a significant radioiodine amount in the stomach, less radioiodine remains available for tumor or thyroid accumulation. This effect may significantly reduce the final dose of 131 I accumulated within tumors. Humans do not concentrate as much radioiodine within the stomach as rodents, suggesting greater tumor accumulation may be achieved in humans with systemic administration of an equivalent 131 I dose. These results imply that the rat NIS gene may be advantageous compared to the human gene in its ability to enhance intratumoral 131 I uptake. However, we recognize that the rat NIS may be more susceptible to immune-mediated destruction since it is a non-human protein. Further improvements, such as utilizing replication-competent viruses for gene delivery, employing alternative isotopes, using gene combinations, and/ or inducing iodine organification, will likely be required for success in human cancer treatment with this novel approach.
We would like to emphasize one more aspect of NISradioiodine therapy which would benefit prostate cancer patients. Current radiation therapy for prostate cancer includes two major modalities: external beam radiation (EBR) therapy, and brachytherapy which involves the insertion of radioactive material (permanent seeds or temporary catheter) into the prostate gland. Prostate cancer treatment is approximately equally effective for both modalities, but the side effects of brachytherapy are more complicated than for EBR therapy and are associated with adverse urinary, bowel, and sexual functions. 26, 27 Our data demonstrated that incubation I dose. The same dose (not presented intracellularly) did not affect the growth of spheroids. This observation may result in the development of an effective cancer treatment based on a designed therapeutic radiation dose that is lethal to cancer cells but less toxic to surrounding healthy tissues.
